Back to Results

Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company listed on the NASDAQ under the ticker KNSA. The company develops and commercializes therapies in the United States, the United Kingdom, and other international markets. Its commercial product, ARCALYST, is used in the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease, and cardiac sarcoidosis. Kiniksa also has pipeline candidates in development, including KPL-387, a fully human monoclonal antibody in Phase 2/3 testing for recurrent pericarditis, and KPL-116, a pre-clinical Fc-modified monoclonal antibody. The company was incorporated in 2015 and is based in London, the United Kingdom. It changed its name from Kiniksa Pharmaceuticals, Ltd. to Kiniksa Pharmaceuticals International, plc in June 2024.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-KNSA
$71.83
-7.9% Downside
Fair
$98
25.6% Upside
Undervalued
Great
0.0%
November 3, 2026
75.6x
9.3x
7.2x
6.086 B
5.579 B
0.1%
51.1%
9.0
226.7%
Valuation • Fair Value

Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) Fair Value by Valuation Model

Review the available estimates for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$71.83

Estimated downside of 7.9% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$76.61

Discounted cash flow valuation reference.

Ben Graham Formula Value

$11.47

Classic Ben Graham valuation formula reference.

Comps Fair Value

$67.05

Comparable-company valuation reference.

Analyst Price Target

$98

Analysts imply upside of 25.6%.

How to read these valuation models

Use the 6 available valuation references for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

840.8 M

Current operating scale indicator.

Revenue Forecast

993.7 M

Forward revenue estimate.

EBITDA

102 M

Current operating profitability reference.

EBITDA Forecast

179.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-3.13

No elevated caution signal from this screen.

Altman Z-Score

9.0

Relatively strong balance-sheet zone.

FCF / Net Income

226.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 3, 2026

Days to Earnings

42

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) Stock Forecast & Technical Outlook

Review Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) has a Strong Buy consensus, with 7 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 0
Sell 0
FAQ • Fast Investor Answers

Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) Stock FAQ

Data-supported answers about Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$71.83
Estimated downside 7.9%
Valuation Rating
Overvalued
Estimated downside of 7.9%
Analyst Target
$98
Implied upside 25.6%
Financial Health
Great
Current financial-health read

The current fair value estimate for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is $71.83. This implies an estimated downside of 7.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 7.9% versus the current market price.

The available analyst price target for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is $98. The analyst target implies estimated upside of 25.6%.

The current financial health read for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is November 3, 2026.

The latest available data indicates no current dividend yield for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA).

The current P/E ratio listed for Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is 75.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Kiniksa Pharmaceuticals Ltd is 6.086 B.

The current enterprise value listed for Kiniksa Pharmaceuticals Ltd is 5.579 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Kiniksa Pharmaceuticals Ltd is NASDAQ-KNSA, and the stock is listed on NASDAQ.

Kiniksa Pharmaceuticals Ltd (NASDAQ-KNSA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Kiniksa Pharmaceuticals Ltd is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Kiniksa Pharmaceuticals Ltd is 51.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B